Clinical Trials for Small Cell Lung Cancer

A Phase 2, Open-label, Randomized Trial to Evaluate Two Dosing Regimens of Subcutaneous Formulation of Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent NSCLC

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adults with previously untreated metastatic or recurrent non-small cell lung cancer (NSCLC) without targetable mutations, testing two dosing regimens of subcutaneous nivolumab (a PD-1 inhibitor) in combination with intravenous ipilimumab (a CTLA-4 inhibitor) and standard chemotherapy. Patients must have measurable disease and good performance status, and those with untreated CNS metastases or active autoimmune disease are excluded.

ClinicalTrials.gov ID: NCT06946797

Open-label, Non-randomized, Multi-cohort, Phase 1b/2 Trial Investigating the Safety, Tolerability, and Antitumor Activity of STC-15 (a METTL3 Inhibitor) as a Part of Combination Therapy With Toripalimab in Participants With Selected Advanced Cancers

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adults with advanced or metastatic NSCLC, melanoma, endometrial cancer, or HNSCC who have progressed after standard therapies including prior anti-PD-1/L1 agents, and evaluates the combination of STC-15 (an oral METTL3 inhibitor targeting RNA methylation) plus toripalimab (anti-PD-1 antibody). Eligible patients must have measurable disease, ECOG 0–1, and no active CNS disease.

ClinicalTrials.gov ID: NCT06975293

Study of NMS-03305293, a Non-Trapping PARP1-Specific PARP Inhibitor in Relapsed Small Cell Lung Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with extensive-stage SCLC relapsing within 6 months after platinum–immunotherapy (and after tarlatamab if appropriate), up to three prior lines, receive oral NMS-03305293 (a PARP1-selective, non-trapping PARP inhibitor) continuously with temozolomide days 1–5 of 28‑day cycles. Single-arm study focuses on safety/PK and preliminary activity in this heavily pretreated population with measurable disease and ECOG 0–2.

ClinicalTrials.gov ID: NCT06931626

RAdiation comBined With BIspecific T-Cell Engager in DLL3 Expressing Tumors (RABBIT) Study: A Phase I/II Study of AMG757 / Tarlatamab and Concurrent Radiation Therapy in Tumors With High Prevalence of DLL3

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with relapsed/refractory DLL3-expressing or DLL3-prevalent tumors (including SCLC, LCNEC, high-grade neuroendocrine tumors, and select NSCLC/other histologies) receive the DLL3-directed bispecific T‑cell engager tarlatamab plus external-beam radiation, given concurrently or sequentially depending on safety. Key risks include CRS/ICANS; includes extracranial and cranial RT cohorts with allowance for treated/stable brain mets and selected brain lesions.

ClinicalTrials.gov ID: NCT06814496

Phase II Clinical Trial of Durvalumab (MEDI4736) and Lurbinectedin in Patients With Relapsed Extensive Stage Small Cell Lung Cancer Previously Treated With Chemotherapy and Immunotherapy

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with relapsed extensive-stage SCLC after exactly one prior line of platinum–etoposide plus a PD-1/PD-L1 inhibitor (including stable treated brain mets) receive durvalumab (anti–PD-L1) combined with lurbinectedin (DNA-binding transcription inhibitor) every 21 days. Includes both platinum-sensitive and -resistant cohorts; key exclusions are active CNS disease, uncontrolled autoimmune/infections, and prior severe ICI toxicity.

ClinicalTrials.gov ID: NCT04607954

A Single Arm Phase II Study Assessing Efficacy of Stereotactic Radiosurgery (SRS) for Brain Metastasis (BM) From Small Cell Lung Cancer (SCLC)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with histologically confirmed SCLC and up to 10 brain metastases (KPS 60–100/ECOG 0–2), without prior brain RT or leptomeningeal disease, receive stereotactic radiosurgery to all lesions. Designed to evaluate intracranial control and short-term survival (6-month OS) with focal SRS instead of whole-brain radiotherapy.

ClinicalTrials.gov ID: NCT05419076

A Randomized, Multi-Cohort Phase II Trial of Temozolomide and Atezolizumab as Second or Third Line Treatment for Small Cell Lung Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with extensive-stage SCLC progressing after platinum-based chemoimmunotherapy (chemo-sensitive or -resistant), ECOG 0–2, measurable disease, and no prior temozolomide are randomized to atezolizumab (anti–PD-L1) plus temozolomide with either a 5-day or extended 14–21 day oral schedule. Stable, asymptomatic brain metastases are allowed; outcomes include response rate, PFS (including intracranial), OS, and safety.

ClinicalTrials.gov ID: NCT04919382

RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with extensive-stage SCLC who have not progressed after 4–6 cycles of platinum/etoposide plus atezolizumab (PR/SD), ECOG 0–2, ≤3 liver mets, and controlled brain mets are randomized to maintenance atezolizumab alone versus atezolizumab plus consolidation external-beam radiotherapy to all disease sites. Atezolizumab is an anti–PD-L1 monoclonal antibody; the study tests whether adding consolidation RT improves PFS/OS versus maintenance alone.

ClinicalTrials.gov ID: NCT04402788

A Phase II Trial of Lamivudine in Combination With Chemoimmunotherapy in Patients With Extensive Stage SCLC

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with extensive-stage SCLC (newly diagnosed or relapse ≥12 months after prior platinum) receive carboplatin/etoposide plus atezolizumab with added lamivudine, followed by maintenance lamivudine ± atezolizumab; patients unable to receive PD-L1 therapy may get chemo plus lamivudine alone. Lamivudine is an oral nucleoside reverse transcriptase inhibitor proposed to inhibit endogenous retroelement RT to reduce resistance and potentially modulate tumor-immune interactions.

ClinicalTrials.gov ID: NCT04696575

Targeted Therapy With CDK4/6 Inhibitors in Chemo- Refractory/Relapsed, Rb Wild-type Extensive Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Lung Cancer, Extrapulmonary Small Cell Cancers and Other High Grade Neuroendocrine Cancers of the Lung, an Open Label Phase 2 Trial.

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with Rb wild-type extensive-stage SCLC, large cell neuroendocrine lung cancer, extrapulmonary small cell cancers, or other high‑grade pulmonary neuroendocrine carcinomas that are platinum‑refractory or relapsed receive single‑agent abemaciclib 200 mg PO BID. Abemaciclib is a selective CDK4/6 inhibitor that blocks Rb phosphorylation to induce G1 arrest; measurable disease and ECOG 0–2 required, treated/stable brain metastases allowed.

ClinicalTrials.gov ID: NCT04010357